Novartis’ generics arm Sandoz has launched the second Healthcare Access Challenge (HACk), which is looking to support digital solutions to local healthcare access challenges.
The competition is open to digital technology entrepreneurs and innovators with ideas with the potential to complement or drive new approaches to improving access to healthcare.
Explaining the rationale behind the competition, Sandoz noted that universal access to healthcare “is still arguably the largest unmet medical need and, while great strides continue to be made globally, access challenges vary hugely across geographies and communities”.
It says digital innovation could provide cost-effective and practical solutions with the power to transform access to healthcare.
“There are still two billion people in this world not getting the medicines they need. This is why we are launching Sandoz HACk as we aim to inspire and embrace the brave and innovative thinking of entrepreneurs and visionaries to improve access to healthcare around the world”, said Richard Francis, division head and chief executive of the firm.
The three shortlisted entrants – which will be announced in January next year – will receive support from Sandoz experts to develop their ideas.
By: Seline Mc Kee
Source: Pharma Times
The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.
Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.
Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.